Literature DB >> 23602370

Magnetic resonance-guided histopathology for improved accuracy of tumor response evaluation of neoadjuvant treatment in organ-infiltrating rectal cancer.

Knut Håkon Hole1, Stein Gunnar Larsen, Krystyna Kotanska Grøholt, Karl-Erik Giercksky, Anne Hansen Ree.   

Abstract

BACKGROUND AND
PURPOSE: The novel procedure of magnetic resonance-(MR) guided histopathology was applied to determine the false-negative rate of conventional histopathologic tumor response evaluation of neoadjuvant radiation/chemoradiation therapy (RT/CRT) in organ-infiltrating rectal cancer.
MATERIALS AND METHODS: Ninety-two consecutive patients that had received RT/CRT and proceeded to extended total mesorectal excision for organ-infiltrating rectal cancer were identified from the institutional database. For each patient, the study radiologist and pathologist separately interpreted preoperative MR images and histologic preparations from the surgical specimen, to determine whether tumor down-staging had resulted. In cases of discrepancy (52 patients), histologic sections were jointly reassessed for residual tumor in areas outside the mesorectal fascial compartment, using MR images as guidance for where to inspect.
RESULTS: Following RT/CRT, 67.5% of cases were found to remain ypT4, even though half of the study population had complete (ypT0; 7.6%) or near-complete (sparsely remaining tumor; 43.5%) histomorphologic tumor regression. After MR-guided histologic reassessment of surgical specimens, the false-negative rate of conventional histopathology for detection of ypT4 was determined to be 41.1%. Five-year estimate for locally recurrent disease was 12.7%.
CONCLUSION: This response data to neoadjuvant RT/CRT in organ-infiltrating rectal cancer indicate that tumor down-staging is over-estimated by conventional evaluation.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23602370     DOI: 10.1016/j.radonc.2013.03.017

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

Review 1.  How Should Imaging Direct/Orient Management of Rectal Cancer?

Authors:  Jemma Bhoday; Svetlana Balyasnikova; Anita Wale; Gina Brown
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

2.  MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.

Authors:  T Seierstad; K H Hole; K K Grøholt; S Dueland; A H Ree; K Flatmark; K R Redalen
Journal:  Br J Radiol       Date:  2015-04-22       Impact factor: 3.039

3.  Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.

Authors:  Helga Helseth Hektoen; Kjersti Flatmark; Yvonne Andersson; Svein Dueland; Kathrine Røe Redalen; Anne Hansen Ree
Journal:  BMC Cancer       Date:  2015-07-24       Impact factor: 4.430

4.  Comparison of time curves from dynamic 18F-fluciclovine positron emission tomography and dynamic contrast-enhanced magnetic resonance imaging for primary prostate carcinomas.

Authors:  Andreas Julius Tulipan; Ljiljana Vlatkovic; Eirik Malinen; Bjørn Brennhovd; Knut Håkon Hole; Agnes Kathrine Lie; Harald Bull Ragnum; Mona-Elisabeth Revheim; Therese Seierstad
Journal:  Phys Imaging Radiat Oncol       Date:  2018-10-02

Review 5.  Contemporary Management of Locally Advanced and Recurrent Rectal Cancer: Views from the PelvEx Collaborative.

Authors: 
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.575

6.  Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer.

Authors:  Sebastian Meltzer; Erta Kalanxhi; Helga Helseth Hektoen; Svein Dueland; Kjersti Flatmark; Kathrine Røe Redalen; Anne Hansen Ree
Journal:  Oncotarget       Date:  2016-06-07

7.  Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening.

Authors:  Erta Kalanxhi; Helga Helseth Hektoen; Sebastian Meltzer; Svein Dueland; Kjersti Flatmark; Anne Hansen Ree
Journal:  BMC Cancer       Date:  2016-07-26       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.